CCR6 and systemic sclerosis: To elucidate the effect of systemic CCR6 inhibition, we need to investigate whether anti-CCR6 neutralizing antibody affects skin fibrosis or other vascular changes, such as PAH, using BLM-treated mice and other SSc animal models recapitulating SSc-PAH.